Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
37results about How to "Decrease the adverse events" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Use of spiro-oxindole compounds as therapeutic agents
ActiveUS8466188B2Improve effectivenessDecrease the adverse eventsBiocideNervous disorderMedicineEnantiomer
Owner:XENON PHARMACEUTICALS INC
Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
InactiveUS20080194616A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderEnantiomerPyridine
This invention is directed to pyridopyrimidinone compounds of formula (I):wherein n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.
Owner:XENON PHARMACEUTICALS INC
Oxindole compounds and their uses as therapeutic agents
InactiveUS20070105820A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderOxindoleDisease cause
Owner:XENON PHARMACEUTICALS INC
Spiro-oxindole compounds and their uses as therapeutic agents
ActiveUS7700641B2Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseMedicine
This invention is directed to spiro-oxindole compounds of formula (I):wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.
Owner:XENON PHARMACEUTICALS INC
Heterocyclic compounds and their uses as therapeutic agents
InactiveUS20080103151A9Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDisease causeStereochemistry
This invention is directed to heterocyclic compounds that are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also disclosed.
Owner:XENON PHARMACEUTICALS INC
Biaryl and biheteroaryl compounds useful in treating iron disorders
InactiveUS20080234384A1Improve effectivenessDecrease the adverse eventsBiocideOrganic chemistryArylEnantiomer
This invention is directed to compounds of formula (I):whereinm, n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.
Owner:XENON PHARMACEUTICALS INC
Dihydroindazole compounds useful in treating iron disorders
InactiveUS20080234327A1Improve effectivenessDecrease the adverse eventsBiocideOrganic chemistryEnantiomerIron disorder
This invention is directed to compounds of formula (I):whereinm, R1, R2, R3 and R4 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.
Owner:XENON PHARMACEUTICALS INC
Spiroheterocyclic compounds and their uses as therapeutic agents
InactiveUS20060252758A1Improve effectivenessDecrease the adverse eventsBiocideSenses disorderDiseaseEnantiomer
This invention is directed to spiroheterocyclic compounds of formula (I) wherein k, j, p, Q, R1, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, that are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also disclosed.
Owner:XENON PHARMACEUTICALS INC
Spiroheterocyclic compounds and their uses as therapeutic agents
InactiveUS7799798B2Improve effectivenessDecrease the adverse eventsBiocideSenses disorderDiseaseEnantiomer
Owner:XENON PHARMACEUTICALS INC
Spiro-oxindole-derivatives as sodium channel blockers
InactiveUS20110269788A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderEnantiomerChannel blocker
This invention is directed to spiro-oxindole compounds of formulas (I), (II), (III), as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.
Owner:XENON PHARMACEUTICALS INC
Biaryl ether sulfonamides and their use as therapeutic agents
InactiveUS20140256736A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEther
Owner:XENON PHARMACEUTICALS INC
Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
InactiveUS20110294842A9Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer
This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein j, k, m, Q, X, R1, R2a, R2b, R2c, R2d and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, N-oxide, solvate or prodrug thereof, for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.
![Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain](https://images-eureka.patsnap.com/patent_img/1ebd3ab6-9e2b-45ac-b2ff-acba37a43ecd/US20110294842A9-20111201-C00001.png "Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain")
![Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain](https://images-eureka.patsnap.com/patent_img/1ebd3ab6-9e2b-45ac-b2ff-acba37a43ecd/US20110294842A9-20111201-C00002.png "Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain")
![Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain](https://images-eureka.patsnap.com/patent_img/1ebd3ab6-9e2b-45ac-b2ff-acba37a43ecd/US20110294842A9-20111201-C00003.png "Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain")
Owner:XENON PHARMACEUTICALS INC
Spiro-oxindole compounds and their use as therapeutic agents
InactiveUS20100099728A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer
Owner:XENON PHARMACEUTICALS INC
Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
InactiveUS20100160291A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer
This invention is directed to tricyclic spiro-oxindole derivatives of formula (I), wherein j, k, m, n, w, q, Y, Q, X, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.
Owner:XENON PHARMACEUTICALS INC
Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
InactiveUS20100160362A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer
This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein j, k, m, Q, X, R1, R2a, R2b, R2c, R2d and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, N-oxide, solvate or prodrug thereof, for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.
![Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain](https://images-eureka.patsnap.com/patent_img/35d4f33d-716a-4dd1-86e5-d03d38ec2191/US20100160362A1-20100624-C00001.png "Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain")
![Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain](https://images-eureka.patsnap.com/patent_img/35d4f33d-716a-4dd1-86e5-d03d38ec2191/US20100160362A1-20100624-C00002.png "Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain")
![Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain](https://images-eureka.patsnap.com/patent_img/35d4f33d-716a-4dd1-86e5-d03d38ec2191/US20100160362A1-20100624-C00003.png "Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain")
Owner:XENON PHARMACEUTICALS INC
Use of spiro-oxindole compounds as therapeutic agents
ActiveUS20100173967A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderEnantiomerMedicine
This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and / or prevention of hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer.
Owner:XENON PHARMACEUTICALS INC
Biaryl ether sulfonamides and their use as therapeutic agents
InactiveUS9481677B2Improve effectivenessDecrease the adverse eventsNervous disorderOrganic chemistryDiseasePharmaceutical medicine
Owner:XENON PHARMACEUTICALS INC
Spiro-oxindole compounds and their uses as therapeutic agents
ActiveUS20060252812A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer
This invention is directed to spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.
Owner:XENON PHARMACEUTICALS INC
Tricyclic compounds useful in treating iron disorders
InactiveUS20090069408A1Improve effectivenessDecrease the adverse eventsBiocideOrganic chemistryDiseaseEnantiomer
This invention is directed to, for example, compounds of formula (I):wherein n, m, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.
Owner:XENON PHARMACEUTICALS INC
Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
InactiveUS20110237567A9Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer
Owner:XENON PHARMACEUTICALS INC
Benzenesulfonamide compounds and their use as therapeutic agents
InactiveUS9630929B2Eliminate side effectsImprove effectivenessNervous disorderOrganic chemistryEnantiomerProdrug
This invention is directed to benzensulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of sodium channel-mediated diseases or conditions, such as pain.
Owner:XENON PHARMACEUTICALS INC
Aromatic and heteroaromatic compounds useful in treating iron disorders
InactiveUS20100240713A1Improve effectivenessDecrease the adverse eventsBiocideHalogenated hydrocarbon active ingredientsEnantiomerIron disorder
This invention is directed to compounds of formula (I), wherein m, formula (II), R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.
Owner:XENON PHARMACEUTICALS INC
Benzenesulfonamide compounds and their use as therapeutic agents
ActiveUS10246453B2Improve effectivenessDecrease the adverse eventsOrganic active ingredientsNervous disorderEnantiomerProdrug
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.
Owner:XENON PHARMACEUTICALS INC
Use of spiro-oxindole compounds as therapeutic agents
ActiveUS20110172282A9Improve effectivenessDecrease the adverse eventsBiocideNervous disorderEnantiomerMedicine
Owner:XENON PHARMACEUTICALS INC
Spiro-oxindole compounds and their use as therapeutic agents
InactiveUS20110112162A9Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer
Owner:XENON PHARMACEUTICALS INC
Benzenesulfonamide compounds and their use as therapeutic agents
InactiveUS20140296245A1Improve effectivenessEliminate side effectsBiocideNervous disorderDiseaseEnantiomer
This invention is directed to benzensulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of sodium channel-mediated diseases or conditions, such as pain.
Owner:XENON PHARMACEUTICALS INC
Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
ActiveUS20200071313A1Increased potencyEliminate side effectsNervous disorderOrganic chemistrySulfonilamideDisease
This invention is directed to heteroaryl-substituted sulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.
Owner:XENON PHARMACEUTICALS INC
Benzenesulfonamide compounds and their use as therapeutic agents
ActiveUS10745392B2Eliminate side effectsUseful in treatmentOrganic active ingredientsNervous disorderDiseasePharmaceutical medicine
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and / or epileptic seizure disorders.
Owner:XENON PHARMACEUTICALS INC
Benzenesulfonamide compounds and their use as therapeutic agents
ActiveUS10815229B1Improve effectivenessDecrease the adverse eventsOrganic active ingredientsNervous disorderDiseaseProdrug
Owner:XENON PHARMACEUTICALS INC
Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
ActiveUS20200157089A1Eliminate side effectsUseful in treatmentOrganic active ingredientsNervous disorderDiseaseAryl
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and / or epileptic seizure disorders.
Owner:XENON PHARMACEUTICALS INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com